What Is the First-Line Treatment of Cutaneous Amoebiasis?
Cutaneous amoebiasis requires treatment directed at two distinct disease compartments: invasive tissue disease and luminal infection. The standard approach uses two separate agents given sequentially, each targeting the phase the other cannot adequately reach.
Treatment Approach
Management follows a two-drug sequential strategy: a tissue-active nitroimidazole is given first to address invasive disease, and must then be followed — not co-administered — by a luminal cysticidal agent to eliminate cysts that nitroimidazoles do not effectively eradicate.
Specific agent selection, dosing, sequencing, and alternatives are detailed in the full structured protocol.
References
DOI: 10.1093/ofid/ofy161
- Patients with clinical disease require treatment with 2 drugs: an amebicidal tissue-active agent and a luminal cysticidal agent.
- The amebicidal agents include metronidazole and tinidazole, which are both nitroimidazole agents.
- They are highly effective at eliminating invading trophozoites and remain the recommended therapy for amebic colitis and amebic liver disease.
- The nitroimidazoles do not effectively eradicate luminal cysts and must be followed by a luminal agent.
- The aminoglycoside paromomycin is a luminal cysticidal agent.
- As it may cause diarrhea, paromomycin should not be administered at the same time as the nitroimidazole agent.
View source ↗